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Abstract
Background: Caryocar brasiliense (pequi) oil is high in monounsaturated fat acids (MUFA), especially oleic, and in
carotenoids, which have been associated with protection against cardiovascular disease. However, this food is
poorly studied in this context, especially in the cardiac function. Therefore, we investigated the effects of a long-
term intake of pequi oil in systemic cardiovascular risk factors and in the ex vivo cardiac function of rats.
Methods: Previously, we determined fatty acids and carotenoids in pequi oil. Next, male rats were divided in C – control
group feed a standard diet, and PO – pequi oil group fed the same diet added pequi oil (+2.25 g.100 g−1). After 15 weeks,
plasma lipids, glucose, insulin, blood pressure, heart rate, hepatic lipids were accessed and visceral fat pads were
harvested. Hearts were used for the ex vivo cardiac function, histologic assays, SERCA2a and phospholanban (PLB)
determinations.
Results: In agreement with scientific data, pequi oil had expressive amounts MUFA, especially oleic acid, and carotenoids.
Hepatic triglycerides (TG) were reduced by pequi oil intake (p < 0.05). All others cardiovascular risk factors were not
changed. The intrinsic heart rate was lower in PO group (p < 0.05). SERCA2a content was higher in this group (p< 0.05),
without affecting PLB. Also, SERCA2a/PLB ratio increased in PO group (p < 0.05).
Conclusion: Pequi oil intake improved cardiac function ex vivo, despite no significant changes in systemic cardiovascular
risk factors. The higher lipid offer in pequi oil diet, its composition in oleic acid and carotenoids could be related to those
effects.
Keywords: Caryocar brasiliense, Monounsaturated fatty acids, Oleic acid, Carotenoids, Cardiac function, Cardiovascular
disease
Background
Cardiovascular diseases (CVD) are responsible for 30%
of all deaths worldwide each year [1] being the high in-
take of lipids one of the major modifiable risk factor in
the etiology of these diseases [2]. Therefore, it has been
indicated the amount and quality of dietary lipid as a
main guideline target for reducing mortality and mor-
bidity by those diseases [2, 3]. In this context, scientific
interest has been particularly directed to the main fatty
acids found in foods: trans, saturated (SFA), polyunsatur-
ated (PUFA) and specially of our interest, monounsatu-
rated (MUFA) fatty acids [4].
Indeed, in foods, some vegetable oils have instigated
interest because their content of MUFA, and, or, PUFA,
which have been associated to health benefits [5]. In this
perspective, pequi oil has a potential for reducing
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cardiovascular risk since it is high in MUFA, beyond
others bioactive compounds that also have been associ-
ated to cardiovascular protection.
This oil is extracted from the Caryocar brasiliense
fruit (pequi) and its major fatty acid is oleic (54%), the
main MUFA in the diet [6]. Scientific evidences sug-
gest that MUFA are associated to coronary heart dis-
ease prevention [7], by favorably improving blood
lipids [8], reducing blood pressure [9], and modulating
insulin sensitivity and glycemic control [10]. Oleic acid
is pointed out as the main responsible for those ef-
fects. In addition, MUFA has also been associated with
improvements in cardiac function, since they are main
components of cardiomyocyte phospholipid mem-
branes, ameliorated endothelial function and reduced
both apoptosis of vessel smooth cells and cardiomyo-
cytes [11, 12].
This oil also has high content of palmitic acid (35%), a
common SFA in animal foods [13]. SFA are more easily
oxidized by cardiomyocytes and they were associated to
improvements in systolic cardiac function [14]. More-
over, fatty acids in general, are cardiac important sources
of energy, since almost 50-70% of ATP used by those
cells, is derived from acetyl coenzyme A (Acetil CoA),
the product of the fatty acids β-oxidation [15].
Pequi oil also has a substantial amount of carotenoids
(8,10 mg.100−1g), especially violaxanthin, lutein, zeaxan-
thin, β-cryptoxanthin, neoxanthin and β-carotene [16,
17]. These compounds also have been related to cardio-
vascular risk reduction. They are potent antioxidants in
biological systems and protect against oxidative damage
[18]. Also, Csepanyi et al. [19] demonstrated that, in
lower doses, these bioactive compounds improved car-
diac function in rat isolated hearts, by langendorff
system.
Therefore, pequi oil is a potential cardiprotector food.
It could favorably modulate cardiac function, and im-
prove systemic cardiovascular risk factors. However, al-
though there are many evidences from its chemical
components related to cardiovascular health, this food
has been poorly studied in this context. To our know-
ledge, there are some research showing healing [20],
chemopreventive [21, 22], anti-mutagenic [23], antioxi-
dant [24], anti-inflammatory, antihypertensive [25] and
anti-cancer [26, 27] properties of pequi oil in humans or
animal models. In addition, most of the information has
not been obtained from its intake. In addition, so far,
there is no research regarding the effects of this oil dir-
ectly in cardiac function.
Therefore, the aim of this study was to evaluate the ef-
fects of a long term pequi oil intake in systemic cardio-
vascular risk factors and in the ex vivo cardiac function
of rats. We also explored the involvement of key pro-
teins that modulate cardiac contractility and relaxation.
Methods
Preliminary analysis of pequi oil
Pequi oil was purchased from the local market in
Diamantina-MG, Brazil. Previously to the rat study, fatty
acids were determined by gas chromatography (CGC
Agilent 6850 Series GC System) according to the AOCS
Ce 1–62 method [28]. Total amount of carotenoids was
determined according the AOAC Official Methods of
Analysis [29], using a spectrophotometer (Specord 210,
model Analytikjena), at 450 nm.
Bioassay design
Sixteen male Wistar rats, 25 days old, were housed in indi-
vidual stainless steel cages and kept in a room at 22 ± 2 °C
and at a 12 h light/dark cycle, with free access to food and
water during all experimental period (15 weeks). In the first
day, all animals were randomly assigned into two treat-
ments: C – control, fed commercial chow (n = 8) (Rhoster-
Lab®, energy density: 328.06 Kcal.100 g−1) or PO – pequi
oil, fed commercial chow added pequi oil (n = 8). Pequi oil
was added to increase by 50% the lipid chow con-
tent(+2.25 g.100 g−1), which also increased its energy dens-
ity up to 348.31 Kcal.100 g−1.
During the experiment, body weight and food intake
were monitored for Feed Efficiency (FER(g/g) = body gain/
food intake) and Energy Efficiency (EER (g/Kcal) = body
gain/energy intake) ratios [30]. In the last day, overnight
fasted animals were anesthetized (quetamin + xilazin/
50 mg/kg + 10 mg/kg), and their nose-anus length were
measured for Lee Index (LI) calculation (LI = [3√body
wheight (g) ÷ nose = anus lenght(cm)] ×10) [30].
After that, all animals were euthanized by decapitation
for blood, livers, hearts, and tissue harvesting. All retro-
peritoneal and epididimal fat pads were removed and
weighted in an analytical scale (Shimadzu AX 200) for the
Adiposity Index calculation (AdI% = (epididimal pad +
retroperitoneal pad)/body weight – (∑epididimal pad +
retroperitoneal pad) *100) [31]. Blood was centrifuged in
heparinized tubes to obtain plasma, which were aliquoted
in eppendorf tubes and kept at -80o C until analysis.
Cardiovascular risk factors assays
Fasted plasma glucose levels (GLU) were measured by a
commercial kit, according the procedures recommended
by the manufacturer and using a semi-automatic bio-
chemical analyzer (PIOWAY-3000). Fasted plasma insu-
lin (INS) was determined using a commercially available
Enzyme-Linked Immunosorbent Assay kit – ELISA
(Linco Research Inc., St. Louis, MO, USA) and a micro-
plate reader (Spectra MAX 190, Molecular Devices,
USA). Insulin resistance was accessed by the homeosta-
sis model assessment of insulin resistance (HOMA-IR
index), from fasted glucose and insulin levels according
to Matthews et al. [32].
Oliveira et al. Lipids in Health and Disease  (2017) 16:37 Page 2 of 8
Total plasma cholesterol (CHOL), high-density lipo-
protein cholesterol (HDL-C), Low-density lipoprotein
cholesterol (LDL-C) and triglycerides (TG) levels were
determined using commercial kits according to the
specifications of the manufacturer and a semi-
automatic biochemical analyzer (PIOWAY-3000). Liver
samples were oven-dried (60 °C ± 2 °C for 72 h), and
their lipids were extracted according to Folch et al.
[33]. CHOL and TG levels were determined using
commercial kits, according to specifications of the
manufacturer, and using a semi-automatic biochemical
analyzer (PIOWAY-3000).
Systolic blood pressure (BP), as well as heart rate
(HR), were measured at the last week prior to the end of
the experiment by the tail-cuff plethysmography method
(MLT1020PPG IR Plethysmograph, PowerLab). Add-
itionally, the double product index was calculated using
systolic blood pressure and heart rate values, as an indi-
cative of cardiac work [34].
Ex vivo analysis and Langendorff preparation
In the last day of the experiment, animals were anes-
thetized (quetamin + xilazin/50 mg/kg + 10 mg/kg) and
decapitated 10–15 min after a 400 IU intraperitoneal
heparin injection. Hearts were perfused in a Langen-
dorff apparatus (ML785B2, ADInstruments) and left
ventricular pressure (± dP/dt) was continuously re-
corded according to the Langendorff technique [35],
using the Labchart 8 software. Systolic tension, dia-
stolic tension, coronary flow, heart rate, and ± dT/dt
values were the average of the recorded 30 min. All
the ± dP/dt measurements were normalized to heart
weight.
Heart/body weight ratio and histologic analysis
At the end of the cardiac function analysis, wet heart
weights were recorded, normalized for the body weight,
and expressed as muscle mass index (mg.g−1), according
to Almeida et al. [36].
For cardiomyocyte diameter, hearts were fixed in 4%
Bouin fixative solution, embedded in paraffin, and sec-
tioned to a5 um thickness. To determine myocyte cross-
sectional area, heart sections were stained with
hematoxylin and eosin and examined at 40× magnifica-
tion. Only myocytes longitudinally cut with the nucleus
centrally located in the cell and with cellular limits vis-
ible were used. The cross-sectional diameter (um) of the
myocytes was traced using ImageJ software (National
Institutes of Health), and determined by averaging 50 to
100 individual cardiomyocytes within the ventricular free
wall over 5 or 6 sections per animal. A single investiga-
tor blinded to the experimental groups performed the
analysis.
Western blotting
Total protein content of left cardiac ventricles was
quantified by means the Bradford protein assay [37].
Protein (80 μg) was loaded onto a 10% polyacryl-
amide gel for electrophoresis. After electrophoresis,
proteins were transferred to a PVDF membrane,
blocked with a phosphate-buffered saline, containing
0.1% Tween 20 and 5% bovine serum albumin. Mem-
branes were incubated overnight at 4 °C with the
following primary antibodies: monoclonal sarcoplas-
mic reticulum Ca2 + −ATPase isoform 2 (SERCA2a)
(1:1000 dilution; Cell Signaling); monoclonal glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) (1:3000
dilution; Cell Signaling); and phopholamban (PLB)
(1:6000 dilution; Cell Signaling). Thereafter, a mono-
clonal anti-rabbit or anti-mouse secondary antibody
conjugated with peroxidase (1:4000 dilution, Cell Sig-
naling) were used. Immunodetection was carried out
using enhanced chemiluminescence (AmershamBios-
ciences), and protein levels were expressed as a ratio
of optical densities.
Statistics
The statistical analyses were carried out using the Statis-
tica 10.0 software. The experiment was carried out in a
completely randomized design. All data obtained from
the experiment are expressed as mean ± standard error.
Statistical differences were evaluated by using one-way
ANOVA. P-values less than 0.05 were considered statis-
tically significant.
Results
Pequi oil had expressive amounts unsaturated fatty acids,
especially oleic acid, a monounsaturated (MUFA),
followed by the linoleic, a polyunsaturated acid (PUFA).
Among saturated fatty acids (SFA), palmitic acid was the
higher (Table 1). Pequi oil also presented 32.18 ± 8 mg/g
of total carotenoids.
In the rat study, at first, pequi oil intake did not affect
body weight and food intake, as well as FER and EER
(Table 2).
We also found that hepatic triglycerides (TG) were re-
duced by pequi oil intake. All others cardiovascular risk
factors were not changed (Table 3).
To address if the treatment with PO could directly
alter cardiac function, we performed Langendorf analysis
(Fig. 1). Rats showed increased basal cardiac function as
evidenced by increased contractility (+dP/dt) [PO:
1640.7 ± 167.7 mmHg/s-1/g-1, C: 1366.9 ± 420.4 mmHg/
s-1/g-1, Fig. 1a] and relaxation (−dP/dt) [PO: 878.5 ±
128.8 mmHg/s-1/g-1, C: 639.5 ± 271.3 mmHg/s-1/g-1,
Fig. 1b] indexes. Furthermore, the intrinsic heart rate
(PO: 198.3 ± 36.8 bpm, C: 244.3 ± 64.4 bpm) was lowered
by pequi oil intake (Fig. 1c).
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Since cardiac function was ameliorated by pequi oil, we
investigated the involvement of key proteins with cardiac
function modulation. We observed an increase in SER-
CA2a content in PO group (Fig. 2a). The same was not
observed for PLB content (Fig. 2b). In addition, the SER-
CA2a/PLB ratio was also higher in PO group (Fig. 2c).
Discussion
Pequi oil, accordingly to data available elsewhere [6, 38,
39], had oleic acid as its major fatty acid, being higher
than olive oil, the main dietary source of it [40]. Other-
wise, the second major fatty acid was palmitic, an im-
portant dietary SFA [41]. High carotenoid content was
also observed. According to Rodriguez-Amaya et al.
[42], to be a carotenoid source, a food must have more
than 20 μg/g, which is associated to health benefits. We
found 10× more carotenoids in pequi oil, so it could be
an excellent carotenoid food source.
Thus, for the rat study, we decided to add pequi oil in
the chow turning its lipid content 50% higher, which
added oleic acid by 1.29 g.100−1 and carotenoids by
7.2 μg.g−1. Also, it increased palmitic acid by 0.83 g.100
−1. According to Hariri and Thibault [9], it is necessary
to increase lipid content of an experimental diet up to
30% of its total energy to induce metabolic disturbance
in rodents. Adding pequi oil to the chow provided
18.51% of lipid energy.
Overall, our data indicated that long term pequi oil in-
take was able improve the ex vivo cardiac function, by
increasing cardiac relaxation and contractility. We also
inferred that this effect occurred independently of
changes in systemic cardiovascular risk factor, since just
hepatic TG was changed by pequi oil.
Indeed, the slightly higher lipid availability from pequi oil
could have contributed to these results. To achieve a better
cardiac function, it is necessary a correct oxygen supply
and energy provision to meet the myocardium demands.
Heart is known by its ability to produce energy from fatty
acids because it is more capable to perform beta-oxidation,
since it has high amounts and activity of enzymes related
to. Heart ATP storage is limited and it can assure just a few
seconds of beating. Because of that, cardiac muscle can
adapt quickly to the energy demand and increases up to
100% its energy production from fatty acids, when there is
higher availability of those nutrients [43].
Otherwise, the nature of the fatty acids in this oil may
also have accounted to these changes. Palmitic acid, the
second higher fatty acid in pequi oil, is oxidized rather
than other fatty acids in heart [44]. Oleic acid, the major
fatty acid in this oil, is able to up-regulate the
Table 1 Fatty acids profile of pequi oil (g.100 g−1)
Fatty acid Carbon num. Mean ± SD
Lauric C12:0 0.04 ± 0.01
Myristic C14:0 0.10 ± 0.01
Palmitic C16:0 37.05 ± 0.04
Stearic C18:0 2.12 ± 0.01
Arachidonic C20:0 0.20 ± 0.01
Behenic C22:0 0.07 ± 0.01
Lignoceric C24:0 0.09 ± 0.01
Palmitoleic C16:1 0.82 ± 0.01
Oleic C18:1 57.42 ± 0.03
Linoleic C18:2 1.38 ± 0.01
α-Linolenic C18:3 0.32 ± 0.01
Eicosenoic C20:1 0.25 ± 0.01
Total saturated — 39.73 ± 0.03
Total unsaturated — 60.27 ± 0.03
Table 2 General characteristics of experimental groups after
15 weeks of treatment
Variables C PO
Body weight (g) 286.4 ± 55.9 277.9 ± 35.0
Food intake (g) 2209.5 ± 237.0 2406.3 ± 230.7
Energy intake (Kcal) 7247.3 ± 895.5 8373.8 ± 802.9
Feed efficiency ratio (g.g−1) 0.10 ± 0.02 0.09 ± 0.01
Energy efficiency ratio (g. Kcal−1) 0.032 ± 0.006 0.027 ± 0.004
C chow, PO Chow added pequi oil; Values are expressed as mean ± standard
error. * indicates statistical difference (p < 0.05) between means by
One way-ANOVA
Table 3 Cardiovascular risk factors of experimental groups after
15 weeks of treatment
Variables C PO
Lee index (g/cm3) 3.1 ± 0.1 2.9 ± 0.2
Adiposity index (%) 2.9 ± 0.7 3.1 ± 0.7
Plama glucose (mg/dL) 123.7 ± 22.1 127.9 ± 9.6
Plasma insulin (ng/mL) 1.0 ± 0.2 1.1 ± 0.3
HOMA-IR 0.28 ± 0.05 0.27 ± 0.08
Plasma cholesterol (mg/dL) 58.1 ± 8.5 62.1 ± 6.6
Plasma triglycerides (mg/dL) 32.6 ± 5.3 33.8 ± 10.6
LDL-C (mg/dL) 14.0 ± 1.2 15.7 ± 1.5
HDL-C (mg/dL) 22.9 ± 5.9 23.0 ± 1.8
Hepatic cholesterol (mg.g−1) 5.9 ± 1.1 4.8 ± 1.6
Hepatic triglycerides (mg.g−1) 23.2 ± 2.4 17.0* ± 2.0
Systolic blood pressure (mmHg) 152.4 ± 21.8 150.7 ± 26.3
Heart Rate (bpm) 392.4 ± 62.2 402.7 ± 67.5
Double product index
(mmHg x bpm)
60451.6 ± 16078.5 61586.5 ± 20209.6
Muscle mass index (mg.g−1) 4.6 ± 0.6 5.0 ± 0.7
Cardiomyocytes diameter (μm) 12.8 ± 0.8 13.1 ± 0.8
C chow, PO Chow added pequi oil; Values are expressed as mean ± standard
error. * indicates statistical difference between means (p < 0.05) by
One way-ANOVA
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transcription of genes coding for proteins involved in
cardiac fatty acid transport and metabolism. These
changes correspond to a 60% increase in cardiomyocyte
fatty acid oxidation capacity [45].
Also, pequi oil intake provided exogenous antioxidants,
especially carotenoids, which also could have accounted
for those effects. Csepanyi et al. [19] showed in a rat
model that carotenoid intake improved heart function at
lower reperfusion times. These authors assigned those ef-
fects to the antioxidant properties of these compounds.
Conversely, although hepatic TG reduction was a
timely result, a previous study from our lab also
showed a significant reduction of those parameters in
rats fed pequi pulp providing a 50% increase of diet-
ary oil [38]. In addition, despite this result could not
be related directly to cardiac function, there is a great
body of evidence connecting hepatic lipid accumula-
tion to cardiovascular risk, independently of coexist-
ing cardiometabolic risk factors [46].
MUFA may exert their beneficial effects on hepatic fat
content through their influence on lipid metabolism in the
liver or in the abdominal adipose tissue [47]. A high MUFA
diet could avoid hepatic lipid accumulation by activating
catabolic pathways. It may result in degradation of the
insulin-induced gene-1 protein, and therefore, inactivation
of the transcription factor sterol regulatory element binding
protein which promotes, among some effects, fat oxidation
[40]. Indeed, an increasing body of evidence indicates an in-
crement in fat oxidation rate, specifically with higher diet-
ary MUFA levels, in several tissues [48, 49]. More recently,
Liu et al. [13] showed in mice that hepatic oleic acid, pro-
vided both by diet or endogenously, is pivotal to prevent or
to solve hepatic stress and inflammation induced by lipo-
genic diets.
Based on the systemic findings, we could infer that the
improved cardiac function in pequi oil group was a conse-
quence of intrinsic cardiac adaptations. The reduced heart
rate and the increased cardiac SERCA2/PLB ratio in pequi
oil group were important changes that can explain that. It
is well established that a decrease in heart rate increases
the diastolic period, which favors improved contractility/
relaxation efficiency. Nevertheless, we believe that the im-
proved cardiac function in pequi oil group was a conse-
quence of the increased SERCA2a/PLB ratio.
It is known that, in rats, 92% of Ca2+ fluxes during car-
diac excitation-contraction is regulated by SERCA2a. It
acts as a sarcoplasmic reticulum (SR) protein regulated by
PLB, facilitating SR calcium storage [50]. During systole,
the action potential induces calcium release from SR and,
the higher calcium availability, the higher contractility.
During diastole, SERCA2a increases calcium reuptake to
SR increasing the efficiency of relaxation [51]. In STZ-
induced diabetic rats, the increase of SERCa2a expression
protected from diabetic cardiomiopaty [52].
a b c
Fig. 2 Pequi oil increases SERCA2a expression (a) and SERCA2a/PLB ratio (c) of rats. C = Chow and PO = Chow added pequi oil. Values are
expressed as mean ± SD. * indicates statistical difference (p < 0.05) by One way-ANOVA
a b c
Fig. 1 Pequi oil improves basal cardiac function and heart rate of rats. C = Chow and PO = Chow added pequi oil. Contractility index (+dP/dt) (a),
relaxation index (−dP/dt) (b) and heart rate (c). Values are expressed as mean ± SD. * indicates statistical difference (p < 0.05) by One way-ANOVA
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PLB is an integral SR membrane protein, which regulates
SERCA2a activity. An upregulation in SERCA2a-to-PLB ra-
tio is an important indicative of increased SERCA2a activity
[53]. Thus, the increased SERCA2a/PLB ratio in pequi oil
animal hearts may be an important mechanism that explain
the increased cardiac contractility/relaxation index.
Still, our study shows some limitations. As there is
no information about human intake of pequi oil as
well as a few ones about doses used previously in ani-
mal models (as a whole food), it is possible that the
amount of pequi oil added has not been sufficient to
promote clearer effects, especially in systemic cardio-
metabolic risk factors. However, we chose to increase
dietary lipids by 50% using pequi oil because we tried
to associate some basic results gotten from pre-tests
and in this way, the diet did not turned into a high fat
[9]. Besides, our research group and others showed,
previously, improvements in systemic cardiovascular
risk factors in rats and humans fed pequi pulp or
pequi oil pills providing 600 mg/d of pequi oil [23–25,
38, 39]. In this way. we would be offering at least,
600 mg/d of pequi oil. Also, we were unable to address
the observed effects to MUFA, or carotenoids or both.
However, at this point of investigation, we were more
interested, in knowing if the whole food intake exerted
any effect. In addition, a complete characterization of
the mechanism and the reasons by which the long
term intake of pequi oil led to lowering hepatic trigly-
ceride deposition, bradycardia and increased SER-
CA2a/PLB ratio is beyond the scope of the present
study and requires future investigations. Moreover, it
is important to point out that this is the first paper
showing cardiovascular effects of long-term pequi oil
intake, especially on cardiac function.
Moreover, future research will be include more profound
molecular analysis not only on calcium transient but also on
the cardiac redox state [54] in hearts of animals feed pequi
oil. It also would be necessary to evaluate if cardioprotective
effects of pequi oil happens to be in other situations, such
as, in different doses of pequi oil that mimic human servings
and, or, in pathological conditions (non-alcoholic fatty liver
disease, obesity, insulin resistance), or at minimal cardiomet-
abolic disturbances, since food bioactive compounds may
not show clear effects in healthy conditions.
Conclusions
Taken together, our data indicates that pequi oil was able
to improve rat ex vivo cardiac function, by increasing car-
diac relaxation and contractility, despite no significant
changes in systemic cardiovascular risk factors. The higher
availability of lipids associated to the higher content of
oleic and palmitic acids and carotenoids provided by pequi
oil diet could be related, at least, in part to those findings.
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